ERBB2 and breast carcinoma: Overexpression of human epidermal growth factor receptor-2 (HER2) is observed in 20–30% of human breast cancers and is associated with a more aggressive phenotype, higher rates of recurrence, and increased mortality compared with HER2-negative BC [1,2].